Clicky

Portage Biotech Inc.(PRTG)

Description: Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.


Keywords: Cancer Immunology Solid Tumors Immune System Antibodies Antiviral Drug Interferon Biotechnology Products Acute Kidney Injury Pharmaceutical And Biotechnology Natural Killer T Cell

Home Page: www.portagebiotech.com

PRTG Technical Analysis

Craigmuir Chambers
Tortola, VG1110
British Virgin Islands
Phone: 416-929-1806


Officers

Name Title
Dr. Ian B. Walters M.B.A., M.D. CEO & Chairman of Board
Mr. Allan J. Lee Shaw CPA Chief Financial Officer
Mr. Steven Innaimo VP of Project Management & Operations
Dr. Robert A. Kramer Ph.D. Chief Scientific Officer
Mr. Brian Wiley Chief Bus. Officer
Mr. Joseph Ciavarella Chief Accounting Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.5308
Price-to-Sales TTM: 0
IPO Date: 2021-02-25
Fiscal Year End: March
Full Time Employees: 6
Back to stocks